Amgen Inc.

AI Score

XX

Unlock

312.80
-2.24 (-0.71%)
At close: Mar 21, 2025, 3:03 PM
-0.71%
Bid 312.72
Market Cap 168.04B
Revenue (ttm) 33.22B
Net Income (ttm) 4.06B
EPS (ttm) 7.56
PE Ratio (ttm) 41.38
Forward PE 13.46
Analyst Hold
Ask 312.8
Volume 2,418,411
Avg. Volume (20D) 3,007,759
Open 311.82
Previous Close 315.04
Day's Range 311.24 - 314.11
52-Week Range 253.30 - 346.85
Beta 0.52

About AMGN

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopaus...

Sector Healthcare
IPO Date Jun 17, 1983
Employees 28,000
Stock Exchange NASDAQ
Ticker Symbol AMGN
Full Company Profile

Analyst Forecast

According to 22 analyst ratings, the average rating for AMGN stock is "Hold." The 12-month stock price forecast is $324, which is an increase of 3.58% from the latest price.

Stock Forecasts

Next Earnings Release

Amgen Inc. is scheduled to release its earnings on May 1, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+6.5%
Amgen shares are trading higher after the company ... Unlock content with Pro Subscription
1 month ago
+0.05%
Amgen shares are trading lower. The company reported Q4 financial results.